Target
TP53
85 products, 78 indications
Indications
Platinum-resistant recurrent ovarian carcinoma (6 products)
glioblastoma (5 products)
Metastatic Cancer (4 products)
NSCLC (4 products)
platinum-resistant high-grade serous ovarian cancer (4 products)
stage IV NSCLC (4 products)
metastatic melanoma (4 products)
Metastatic Castration-Resistant Prostate Cancer (3 products)
stage III non-small cell lung cancer (3 products)
unresectable stage 3 NSCLC (3 products)
unresectable stage IIIA/IIIB NSCLC (3 products)
ovarian cancer (3 products)
Ovarian Cancer (3 products)
Advanced Epithelial Ovarian Cancer (2 products)
extensive-stage SCLC (2 products)
advanced malignancies (2 products)
biliary tract cancer (2 products)
advanced urothelial carcinoma (2 products)
Unresectable hepatocellular carcinoma (2 products)
metastatic non-small cell lung cancer (2 products)
Low-grade serous ovarian cancer (2 products)
stage IV metastatic melanoma (2 products)
Platinum-sensitive recurrent ovarian carcinoma (2 products)
high grade serous ovarian carcinoma (2 products)
platinum-resistant/refractory epithelial ovarian cancer (2 products)
Resectable Pancreatic Ductal Adenocarcinoma (1 products)
metastatic soft tissue sarcoma (1 products)
advanced, metastatic solid tumors (1 products)
pancreatic cancer (1 products)
Oligometastatic pancreatic ductal adenocarcinoma (1 products)
non-metastatic castration-resistant prostate cancer (1 products)
MSI-H metastatic castration-resistant prostate cancer (1 products)
oesophageal squamous cell carcinoma (1 products)
Advanced extrahepatic cholangiocarcinoma and gallbladder cancer (1 products)
Stage IIIA NSCLC (1 products)
EGFR-negative refractory advanced NSCLC (1 products)
Endometrial and ovarian cancer (1 products)
Advanced/metastatic osteosarcoma (1 products)
Advanced soft tissue sarcoma (1 products)
Unresectable locally advanced/locally recurrent esophageal cancer or esophagogastric junction cancer (1 products)
recurrent or metastatic head and neck squamous cell carcinoma (1 products)
Advanced ovarian cancer and colorectal cancer (1 products)
metastatic cutaneous melanoma (1 products)
Advanced or metastatic gastrointestinal cancers (colorectal, gastric, gastroesophageal) (1 products)
metastatic castration-sensitive prostate cancer (1 products)
metastatic ovarian cancer (1 products)
Early stage epithelial ovarian cancer (1 products)
Advanced high-grade ovarian cancer (1 products)
Unresectable ovarian cancer (1 products)
recurrent advanced ovarian cancer (1 products)
High-risk non-muscle invasive bladder cancer (1 products)
Prostate cancer (1 products)
Lung cancer (1 products)
resectable stage II - III non-small cell lung cancer (1 products)
melanoma or lung cancer with autoimmune disease (1 products)
melanoma or lung cancer without autoimmune disease (1 products)
resectable squamous non-small cell lung cancer (1 products)
Advanced melanoma (1 products)
mucosal melanoma (1 products)
Unresectable Melanoma (1 products)
Melanoma and Merkel Cell Carcinoma (1 products)
high-risk stage IIIB–IV cutaneous melanoma (1 products)
urothelial carcinoma (1 products)
relapsed/refractory NSCLC (1 products)
HER2-low metastatic breast cancer (1 products)
Pregnancy-associated melanoma (1 products)
Gastroesophageal Junction Adenocarcinoma, Gastric Cardia Adenocarcinoma (1 products)
hepatocellular carcinoma (1 products)
Relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma (1 products)
Locally advanced non-small cell lung cancer (1 products)
HR+/HER2- early-stage breast cancer (1 products)
NRAS-mutant unresectable stage III or IV melanoma (1 products)
advanced non-squamous NSCLC (1 products)
recurrent ovarian, fallopian tube and primary peritoneal cancer (1 products)
Non-Small Cell Lung Cancer (1 products)
recurrent ovarian cancer (1 products)
Unresectable stage III non-small cell lung cancer (1 products)
Melanoma (1 products)
Loading...
1 product
1 drug
144 abstracts
Abstract
Efficacy and safety of ibrutinib plus venetoclax in patients with mantle cell lymphoma (MCL) and TP53 mutations in the SYMPATICO study.Org: The University of Texas MD Anderson Cancer Center, Maria Skłodowska-Curie National Research Institute of Oncology, General University Hospital in Prague, Charles University Hospital and Faculty of Medicine, Wrocław Medical University,
Abstract
Benefit of rituximab maintenance after first-line bendamustine-rituximab in mantle cell lymphoma.Org: Mayo Clinic, Memorial Sloan Kettering Cancer Center, Cleveland Clinic Lerner College of Medicine, The Ohio State University - Division of Hematology, Washington University School of Medicine,
Abstract
A clinical-genetic (CG) circulating tumor DNA (ctDNA)-based prognostic model for predicting overall survival (OS) in men with metastatic castrate-resistant prostate cancer (mCRPC) treated with potent androgen receptor inhibition (Alliance).Org: Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University School of Medicine, Duke University Medical Center, Duke University Department of Biostatistics and Bioinformatics,
Abstract
Molecular profiling after short-term preoperative endocrine therapy to identify oestrogen receptor positive (ER+)/HER2+ early breast tumours with favourable prognosis.Org: Institute of Cancer Research, London, United Kingdom, Royal Marsden Hospital, London, United Kingdom, The Institute of Cancer Research, London, United Kingdom, The Institue of Cancer Research, London, United Kingdom, The Institute of Cancer Research, Sutton, United Kingdom,
Abstract
Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study.Org: Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, Medical Oncology, Regional University Hospital of Málaga, Málaga, Spain, Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia, Paris-Saclay University, Gustave Roussy Cancer Center, Villejuif, France,
Abstract
Genomic and transcriptomic biomarkers of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancer.Org: Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milano), Italy, CHA University School of Medicine, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, CHA Bundang Medical Center, Department of Surgery, Brigham and Women's Hospital, Boston, MA,
Abstract
Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations.Org: Department of Medicine, Medical Oncology, Memorial Sloan Kettering Cancer Center,
Abstract
Phase 1/2 trial of the XPO1 inhibitor selinexor in combination with docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer (NSCLC).Org: Newton, MA,
Abstract
ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy.Org: Taipei, Taiwan, Sutter/California Pacific Medical Center, Nanjing Bayi Hospital, Nanjing, Jiangsu, China, Ibaraki, Japan,
Abstract
Association of germline HSD3B1 (c.1100) genotype with tumoral and clinical outcomes in breast and endometrial cancers.Org: University of South Carolina,
Abstract
Treatment of patients with dedifferentiated liposarcoma (DDLPS) with the MDM2–p53 antagonist brigimadlin and p53 function: A longitudinal analysis of circulating microRNAs (miRNAs) in a first-in-human phase Ia/Ib study.Org: Boehringer Ingelheim Pharma GmbH & Co. KG, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, National Cancer Center Hospital East, Kashiwa, Japan, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland,
Abstract
Final analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer KRAS G12C mutation.Org: Wakayama Medical University Hospital, Wakayama-Shi, NA, Japan, Department of Respiratory Medicine, Kumamoto University Hospital, Kumamoto, Japan, Kurume University School of Medicine, Fukuoka, Japan, Department of Respiratory and Allergy Medicine, Nagoya City University Hospital, Nagoya, Japan, Kitakyushu Municipal Medical Center, Kitakyushu, Japan,
Abstract
TOP: A phase III, multicentre, randomized controlled study comparing osimertinib in combination with carboplatin and pemetrexed to osimertinib monotherapy for untreated patients with advanced non-squamous (Non-sq) non-small cell lung cancer (NSCLC) with concurrent EGFR and TP53 mutations.Org: Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China, The First People's Hospital of Foshan, Foshan, China, Department of Respiratory Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China, Central Hospital of Guangdong Provincial Nongken, Zhanjiang, China, Henan Cancer Hospital, Zhengzhou, China, Taizhou First People's Hospital, Taizhou, China, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China, The First People's Hospital of Changzhou, Changzhou, China, Shengli Oilfield Central Hospital, Dongying, China, Taizhou Central Hospital, Taizhou, China, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China,
Abstract
Alisertib in patients with extensive-stage small-cell lung cancer: The phase 2 ALISCA-Lung1 study.Org: Puma Biotechnology Inc.,
Abstract
Innovation of the first-line strategy optimized as abemaciclib with endocrine therapy based on the ESR1 mutation of ctDNA for patients with HR-positive HER2-negative advanced metastatic breast cancer (JBCRG-M08; AMBER study).Org: Osaka University Hospital, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR), Nagoya University Hospital,
Abstract
Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC).Org: Severance Hospital Yonsei University Health System, University of Auckland, Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, National Yang Ming Chiao Tung University,
Abstract
Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the phase 3 Pola-R-CHP versus R-CHOP (POLARIX) study.Org: Centre Henri-Becquerel and University of Rouen, University Hospital Münster, M.D. Anderson Cancer Center, Charles University General Hospital, University of Montpellier,
Abstract
Insights from C-CAT repository: A novel approach to identifying appropriate patient populations for anticancer drug development using the clinicogenomic nationwide database in Japan.Org: National Cancer Center Research Institute, National Cancer Center Hospital East, Kashiwa, Japan, Division of Genome Biology, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Department of Experimental Therapeutics, National Cancer Center Hospital East,
Abstract
Genomic and biomarker analysis of immunotherapy combined with chemotherapy treated for patients with metastatic BTC cancer: A real world study.Org: Chinese People's Liberation Army General Hospital, Chinese People’s Liberation Army General Hospital, Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital,
Abstract
Effect of longitudinal ctDNA monitoring with resistance genomic signatures on prognostication in patients with EGFR-mutated advanced NSCLC.Org: Pune, Advanced Centre for Treatment Research and Education in Cancer, Navi Mumbai, Cupertino, CA,
Abstract
Prediction of recurrence in stage I EGFR mutation-positive NSCLC: Combination of CT appearance and selected co-occurring gene alterations by machine learning.Org: Division of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, Japan, Department of Thoracic Oncology , National Cancer Center Hospital, Tokyo, Japan, Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan, Department of Radiation Oncology, National Cancer Center Hospital, Japan, Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan,
Abstract
Integrative genomic analysis examines molecular and clinical disparities between bladder urothelial carcinoma and upper tract urothelial carcinoma.Org: Konyang University Hospital,
Abstract
Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4/6 inhibitors: Results from the AURORA Molecular Screening Initiative.Org: Université Libre de Bruxelles (ULB), Breast Cancer Translational Research Laboratory J.-C. Heuson, Institut Jules Bordet, Hôpital Universitaire de Bruxelles (HUB), Université Libre de Bruxelles (ULB), Brussels, Belgium, Breast International Group, Brussels, Belgium, Dana-Farber Cancer Institute, Vall d’Hebron Institute of Oncology (VHIO),
Abstract
Characterization of cell-free circulating tumor DNA in patients with brain metastases.Org: UC San Diego Moores Cancer Center, Center for Personalized Cancer Therapy and Division of Hematology and Oncology, UCSD Moores Cancer Center, UC San Diego Medical Center, UC San Diego,
Abstract
Association of somatic mutations and histologic subtype/grade on prognosis and PD-L1 expression in mesothelioma.Org: University of Chicago, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, University of Chicago Bucksbaum Institute for Clinical Excellence, Section of Hematology/Oncology, The University of Chicago Medicine,
Abstract
The genomic and transcriptomic landscapes of chemotherapy naïve vs post-chemotherapy germ cell tumors.Org: University of California San Diego Health, CanSino Biologics, La Jolla, CA, UT Southwestern Medical Center, Txinno Bioscience,
Abstract
Genomic targetability and survival outcomes of biliary tract cancers (BTC): A retrospective cohort study of the Australian Molecular Screening and Therapeutics (MoST) program.Org: Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Chris O'Brien Lifehouse, Royal North Shore Hospital, Sydney, Australia, Westmead Cancer Care Centre,
Abstract
Identification and management of clonal hematopoiesis of indeterminate potential (CHIP) in cancer survivors: The Cleveland Clinic experience.Org: Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Institute, Sylvester Comprehensive Cancer Center, Miami, FL,
Abstract
Cancer of unknown primary with gastrointestinal profiles: A distinct CUP subset.Org: Baylor College of Medicine, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, MD Anderson Cancer Center Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Ancestry-adjusted genomic analysis to identify known and novel associations with single and multiple cancer phenotypes.Org: Memorial Sloan Kettering Cancer Center,
Abstract
The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC): Results from a prospective observational reference laboratory testing program.Org: Durham, NC, Labcorp Oncology, Nykode Therapeutics, Buffalo, Duke University Medical Center,
Abstract
A phase IIa/IIb, open-label trial of BI 907828, an MDM2–p53 antagonist, in patients with locally advanced/metastatic biliary tract carcinoma or pancreatic ductal adenocarcinoma: Brightline-2.Org: Boehringer Ingelheim (People’s Republic of China) Investment Co., Ltd., Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH,
Abstract
Outcome of TP53-mutated CCUS and the risk of progression to myeloid neoplasms.Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ,
Abstract
Clinical utility of next generation sequencing (NGS) on circulating tumor DNA (ctDNA) in patients (pts) with pancreatic cancer (PC).Org: Memorial Sloan Kettering Cancer Center, Brigham and Women's Hospital/Massachusetts General Hospital, Department of Epidemiology & Biostatistics, Mount Sinai Morningside West, Icahn School of Medicine at Mount Sinai Morningside/West,
Abstract
Safety and efficacy of Sleeping Beauty TCR-T cells targeting shared KRAS and TP53 mutations expressed by solid tumors in first-in-human phase 1 study.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Alaunos Therapeutics,
Abstract
Not all treated KRAS-mutant pancreatic adenocarcinomas are equal: KRAS G12D and survival outcome.Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Maryland Capital Region, Caris Life Sciences, Irving, TX, Hoag Memor Hosp, University of Kansas Cancer Center, Kansas City, KS,
Abstract
Accuracy of genome-wide mutational analysis for tumor-informed ctDNA-guided MRD monitoring in bladder cancer.Org: Aarhus University Hospital, C2i Genomics Inc., C2i Genomics Ltd.,
Abstract
Prevalence of unexpected actionable germline pathogenic variants identified on broad-based multi-gene panel testing in a cohort of cancer patients.Org: University of Vermont Larner College of Medicine, Dana-Farber Cancer Institute,
Abstract
Genomic characterization of somatic mutations by race and ethnicity in pancreatic cancer defined through AACR project GENIE.Org: Laboratory of Molecular Biology, NCI, NIH, Bethesda, MD, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program,
Abstract
Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA.Org: Guardant Health, Inc., Mayo Clinic Florida, Mayo Clinic, Emory University, Atlanta, GA, USA, Miami Cancer Institute - Baptist Health South Florida,
Abstract
Molecular characterization of resistance to immune checkpoint inhibitor and chemotherapy treatment in advanced non-small cell lung cancer.Org: Gilead Sciences,
Abstract
Evaluation of genomic alterations in early-onset versus late-onset colorectal cancer.Org: Natera, Inc., Natera, Inc, Vanderbilt-Ingram Cancer Center,
Abstract
Clinical genomic implications of transcriptional subtypes in pancreatic cancer.Org: Dana-Farber Cancer Institute, Brookline, MA, Boston, MA, Caris Life Sciences, Irving, TX, Phoenix, AZ,
Abstract
Ultra-sensitive, tumor-informed ctDNA profiling in patients with gastroesophageal cancer and treated with pembrolizumab and longitudinal ctDNA kinetics.Org: Duke University Medical Center, Personalis, Inc., University of North Carolina at Chapel Hill, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
Outcomes of 10-day decitabine with venetoclax for AML.Org: Medical University of South Carolina Hollings Cancer Center,
Abstract
Genetic heterogeneity between paired primary and metastatic solid tumors and implications for neoantigen-based personalized cancer vaccines.Org: H. Lee Moffitt Cancer Center and Research Institute, M2GEN, Huntsman Cancer Institute at the University of Utah, Stephenson Cancer Center, Ohio State University Wexner Medical Center,
Abstract
Association of C-MYC, MYC target gene, and unfolded protein response (UPR) expression with clinical benefit from the oral aurora kinase A (AURKA) inhibitor, alisertib (A), in combination with paclitaxel (P) compared with P alone in patients (Pts) with HER2-negative metastatic breast cancer (MBC).Org: Integrated Cancer Genomics Division, Translational Genomics Research Institute (TGen North), Phoenix, AZ, Translational Genomics Research Institute, Phoenix, AZ, Translational Genomics Research Institute (Phoenix, AZ),
Abstract
Trastuzumab (T) plus gemcitabine-cisplatin (GC) for treatment naïve HER2 positive biliary tract adenocarcinomas (BTC): A multicentre open-label, phase II study (TAB).Org: Tata Memorial Hospital (HBNI), Tata Memorial Centre, Homi Bhabha cancer hospital and research centre, Tata Memorial Center (HBNI),
Abstract
Multi-omic characterization of RCC1 expression and its association with molecular alterations, immune phenotypes, and cancer outcomes.Org: University of California Irvine School of Medicine, Barbara Ann Karmanos Cancer Institute, Lombardi Comprehensive Cancer Center, Caris Life Sciences, Irving, TX, Montefiore Einstein Center for Cancer Care,
Abstract
Circulating tumor DNA (ctDNA) monitoring to inform maintenance outcomes in patients (pts) with advanced NSCLC treated with induction atezolizumab+carboplatin+nab-paclitaxel (A+CnP).Org: H. Lee Moffitt Cancer Center and Research Institute, Foundation Medicine, Inc., Cambridge, MA, Genentech Inc., Natera, Inc., Genentech,
Abstract
ctDNA mutational profiles in luminal breast cancer with early vs late distant relapse: Geicam/2014-03.Org: Fundación Instituto Valenciano de Oncología (FIVO), GEICAM Spanish Breast Cancer Group, Valencia, Spain, GEICAM Spanish Breast Cancer Group, Barcelona, Spain, Hospital Universitario de Donostia-BioDonostia, Hospital de la Santa Creu i Sant Pau, Hospital Universitario de Canarias,
Abstract
CDH1-mutated clinically advanced urothelial bladder cancer (UBC): A genomic landscape and real-world clinical outcome study (RWCOS).Org: H. Lee Moffitt Cancer Center and Research Institute, Vita-Salute San Raffaele University, Saint Louis University Hospital, University of Washington; Fred Hutchinson Cancer Center, SUNY Upstate Medical University,
Abstract
Genetic ancestry associations with somatic mutations in a real-world cohort of over 3,000 patients with prostate cancer.Org: Tempus Labs, Inc., Tempus AI, University of Southern California Marshall School of Business,
Abstract
Genomic landscapes of early-onset versus average-onset colorectal cancer populations.Org: Mayo Clinic, Department of Quantitative Science Research, Vanderbilt-Ingram Cancer Center, University of Colorado Cancer Center, Tempus Labs, Inc.,
Abstract
Outcomes of individuals with clonal hematopoiesis evaluated at a cancer center.Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Hematopathology, Beijing Friendship Hospital, Capital Medical University,
Abstract
Multi-factor dynamic analysis of ctDNA and CTC to aid the diagnostic prognosis of patients with metastatic breast cancer (MBC).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, CTC Core Facility, Lurie Cancer Center,
Abstract
EGFR assessment using next generation sequencing as a reflex testing on surgically resected non-squamous non-small cell lung carcinoma.Org: Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, FHU OncoAge, Université Côte d’Azur, CHU Nice,
Abstract
Real-world (RW) use of venetoclax (VEN) in patients (pts) with acute myeloid leukemia (AML) in a US RWE database (COTA).Org: Novartis Pharma AG, Novartis Oncology, Genesis Research, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Yale School of Medicine,
Abstract
Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study.Org: University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, MD Anderson Hematology/Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Washington and Fred Hutchinson Cancer Research Centre,
Abstract
Genomic landscape of multiple myeloma with extramedullary disease: Results from a large patient database.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, University College Dublin Medical School,
Abstract
Co-mutational status and PD-L1 expression in KRAS mutant non-small cell lung cancer (NSCLC): Role in treatment selection and association with clinical outcomes.Org: Caris Life Sciences, Irving, TX, Fox Chase Cancer Center, Barbara Ann Karmanos Cancer Institute, Memorial Cancer Institute, West Cancer Center and Research Institute,
Abstract
A step toward genomic equity: Mutational profiling of patients with myeloid neoplasm in the largest minority-serving hospital in metropolitan Chicago.Org: John H. Stroger, Jr. Hospital of Cook County, Chicago, IL,
Abstract
Risk reclassification of endometrial cancer according to molecular profiling: UK single centre experience.Org: The Royal Marsden Hospital, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, The Royal Marsden Hospital NHS Foundation Trust, Royal Marsden Hospital and Institute of Cancer Research,
Abstract
The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.Org: Yale Cancer Center, Yale School of Medicine, New Haven, CT, Tempus Labs, Inc., David Geffen School of Medicine UCLA, Ohio State University Comprehensive Cancer Center,
Abstract
Superior outcomes after allogeneic stem cell transplantation (SCT) among patients (Pts) ≥ 60 years (yrs) treated with cladribine (CLAD), low dose cytarabine (LDAC) plus venetoclax (Ven) for newly diagnosed acute myeloid leukemia (AML).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation & Cellular Therapy,
Abstract
Integrated clinical, pathologic, and genetic data in a racially diverse hereditary breast cancer cohort.Org: Vanderbilt University Medical Center, Meharry Medical College, Nihon Medi-Physics, Vanderbilt-Ingram Cancer Center,
Abstract
Evolution of genomic profiles in primary and recurrent brain gliomas.Org: Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, Center of Oncocytogenomics, Intitute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and First Faculty of Medicine, Charles University in Prague, Prague 2, Czech Republic, Center of Oncocytogenomics, Institute of medical Biochemistry and Laboratory Diagnostics,General University Hospital and 1st Faculty of Medicine, Charles Unive, Prague, Czech Republic, Center of Oncocytogenomics, Institute of Medical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles Unive, Praha 2, Czech Republic, Institute of Hematology and Blood Transfusion, Prague, Czech Republic, Department of Neurosurgery and Neurooncology, First Faculty of Medicine of Charles University and Military University Hospital Prague, Prague, Czech Republic,
Abstract
TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.Org: Gustave-Roussy Cancer Campus, Institut Claudius Regaud, IUCT-Oncopole Toulouse, Institut Paoli Calmettes, Biostatistic Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy,
Abstract
Pattern of molecular testing among US veterans with gastrointestinal cancers: A single center experience.Org: Veterans Affairs Medical Center, Oklahoma City, OK, Oklahoma City VA Health Care System,
Abstract
Cell-free urinary tumor DNA to detect minimal residual disease prior to repeat-transurethral resection of bladder tumor in non-muscle invasive bladder cancer: A prospective study.Org: H. Lee Moffitt Cancer Center and Research Institute, Predicine, Inc., Predicine Inc., Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute,
Abstract
Multi-omic characterization of gastrointestinal stromal tumor (GIST) in a large real-world patient cohort.Org: Sylvester Comprehensive Cancer Center, Miami, FL, University of Miami Miller School of Medicine, Miami, FL, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Caris Life Sciences, Irving, TX, Lombardi Comprehensive Cancer Center,
Abstract
Detecting variation of clonal hematopoiesis using machine-learning in liquid biopsy.Org: ChosenMed Technology (Zhejiang) Co., Ltd., Beijing, China, ChosenMed Technology (Zhejiang) Co., Ltd., Beijing, Beijing, China, ChosenMed Technology (Zhejiang) Co., Ltd, Beijing, Beijing, China,
Abstract
Prevalence of germline variants in patients with pancreatic neuroendocrine tumors.Org: Johns Hopkins University School of Medicine, University of Texas MD Anderson Cancer Center, University of Pennsylvania, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, University of Texas at MD Anderson Cancer Center,
Abstract
Stimulator of interferon gene (STING) expression as a biomarker for overall survival in PDL1-negative, TMB-low non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs).Org: Caris Life Sciences Research and Development, Caris Life Sciences, Irving, TX, Montefiore Einstein Center for Cancer Care, Lombardi Comprehensive Cancer Center, Georgetown University, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK,
Abstract
The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.Org: Mount Sinai Health System, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Dana-Farber Cancer Institute, SWOG Statistical Center,
Abstract
Biomarkers to predict the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer with actionable genetic alterations.Org: SAIHST, Sungkyunkwan University of Medicine, Samsung Medical Center,
Abstract
Trends in the needs and clinical utility of comprehensive genomic profiling test in rare cancers before and after the National Health Insurance coverage in Japan.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Cancer Center Research Institute,
Abstract
Clinical and molecular characterization of a cohort with breast cancer brain metastases.Org: Oregon Health & Science University, Portland, OR, Internal Medicine Residency,
Abstract
A phase 2 study of alrizomadlin, a novel MDM2/p53 inhibitor, in combination with pembrolizumab for treatment of patients with malignant peripheral nerve sheath tumor (MPNST).Org: Ascentage Pharma Group, Ascentage Pharma (Suzhou) Co., Ltd., State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital,
Product
TMZAbstract
Tp53 as a potential therapeutic biomarker in patients with recurrent high-grade glioma treated with anlotinib and temozolomide.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Henan Provincial People's Hospital and People's Hospital of Henan University, People's Hospital of Henan University, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University,
Abstract
Exploratory novel biomarker and resistance mechanism of milademetan, an MDM2 inhibitor, in amplified MDM2 intimal sarcoma from an open-label phase 1b/2 trial (NCCH1806/MK004).Org: Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, Wakayama Medical University Hospital, Wakayama, Japan, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, National Cancer Center Hospital, Tokyo, Japan, Department of International Clinical Development, National Cancer Center Hospital, Tokyo, Japan,
Abstract
Novel genomic alterations and transcriptomic-based tumor microenvironment classification of sarcoma and their impact on treatment decision making.Org: BostonGene, Corp., Waltham, MA, BostonGene Corporation, University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Next generation sequencing reveals targetable mutations in multiple sarcoma histologies.Org: Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Vanderbilt University School of Medicine, Vander Ingram Cancer Center, Division of Epidemiology and Community Health,
Abstract
Validation of a breast cancer polygenic risk score in 15,490 Brazilians using exome sequencing.Org: Mendelics, Instituto D’Or de Pesquisa e Ensino (IDOR), Center for Clinical Cancer Genetics and Global Health, The University of Chicago, Chicago, IL, The University of Chicago Medicine Center for Advanced Care at Orland Park, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL,
Abstract
Clinical synergy of universal paired tumor genomic and germline sequencing in an unselected, pan-cancer cohort of patients: Greater than the sum of the parts.Org: Invitae, Mayo Clinic, Mayo Clinic Cancer Center Scottsdale, Mayo Clinic in Arizona, Division of Gastroenterology and Hepatology, Mayo Clinic,
Abstract
Validation of a 56 gene panel for the detection of somatic variants in metastatic breast cancer.Org: Epic Sciences, Inc.,
Abstract
Screening the key pathogenic mutations in Chinese patients with colorectal cancers using liquid and tissue biopsy.Org: Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, The First Affiliated Hospital of Harbin Medical University, Harbin, China, HaploX Biotechnology, Shenzhen, China, Shenzhen TargetRx,
Abstract
Clinical utility of plasma ctDNA sequencing monitoring and tumor molecular profile exploration in endometrial carcinoma: A Caribbean prospective cohort from Martinique.Org: Centre Hospitalier Universitaire de Martinique, Institut Gustave Roussy, CHU Martinique,
Abstract
Genomic characterization in gastrointestinal cancer patients based on cfDNA sequencing.Org: Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Longgang District People's Hospital, HaploX Biotechnology, Shenzhen, China,
Abstract
Phase I/II study of nab-paclitaxel combined with S-1 as adjuvant chemotherapy in diffuse type of stage III gastric or gastroesophageal junction adenocarcinoma.Org: Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, China, Department of Oncology, Cancer center, Zhongshan Hospital, Fudan University, Shanghai, China,
Abstract
Effect of somatic-germline genomic integration on the contribution of pathogenic germline genetic variants (gPV) to colorectal cancer (CRC) carcinogenesis.Org: Memorial Sloan Kettering Cancer Center, New York, NY, Clinical Genetics Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, Division of Solid Tumor Oncology, Memorial Sloan Kettering Cancer Center, New York, NY,
Abstract
Association of circulating tumor DNA with survival in neoadjuvant-treated triple negative breast cancer independent of pathological complete response.Org: Fujian Medical University Union Hospital, Department of General Surgery, Chang Gung Memorial Hospital at Tao-Yuan, Tao-Yuan, Taiwan,
Abstract
A pilot study evaluating somatic mutational burden and signatures among endometrial cancer patients: Is there prognostic benefit to whole genome sequencing?Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC, Nykode Therapeutics, Cornell University, Morehouse School of Medicine,
Abstract
Genomic profiling of cerebrospinal fluid ctDNA to characterize molecular features and monitor intracranial responses of patients with osimertinib-resistant non-small cell lung cancer with leptomeningeal metastases.Org: 3D Medicines Inc.,
Abstract
Clinical utility of reporting research genetic predisposition testing results to Total Cancer Care participants.Org: University of Kentucky Markey Cancer Center, University of Kentucky Chandler Medical Center, University of Kentucky, Lexington, KY, Department of Pathology and Laboratory Medicine University of Kentucky Chandler Medical Center, Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, University of Kentucky College of Medicine,
Abstract
Molecular profile of SWI/SNF complex in Chinese patients with ovarian cancer.Org: Nanjing Simcere Medical Laboratory Science Co., Ltd Nanjing, China, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,
Abstract
Somatic hereditary gene panel analysis: A pilot study from Uzbekistan.Org: Vita Alliance Hospital, Tashkent, Uzbekistan,
Abstract
Clinical implications of recurring mutations in myxoid liposarcoma (MLS).Org: University of Texas MD Anderson Cancer Center, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center,
Abstract
Treg cells and the response to neoadjuvant chemotherapy combined with immunotherapy in resectable esophageal squamous carcinoma.Org: The Third Affiliated Hospital of Soochow University, Changzhou, China, Changzhou Qianhong Bio-pharma, China National Biotec Group, Medical Department, 3D Medicines Inc.,
Abstract
Co-occurrence of mutations and related signal pathway analysis of CCND1 amplification in esophageal squamous cell cancer.Org: Tianjin Medical University Cancer Institute and Hospital/National Clinical Research Center for Cancer, Tianjin, Tianjin, China, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China, Tianjin Tumor Hospital, Tianjin, China, Hangzhou Repugene Technology Co,.Ltd, Hangzhou, China, Hangzhou Repugene Technology Co., Ltd., Hangzhou, China,
Abstract
ENGOT-EN20/GOG-3083/xport-EC-042: A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with P53 wild-type, advanced or recurrent endometrial carcinoma.Org: University Hospitals Leuven, Leuven, Belgium, Leuven Cancer Institute, BGOG, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Copenhagen University Hospital,
Abstract
Prevalence of pathogenic variants in non-BRCA genes and their impact on clinical practice in Argentina.Org: Hospital Privado Universitario de Córdoba, CIMETSA-IUCBC,
Abstract
Mutation profiling of gliomas based on sex, age, and family history.Org: Shenzhen Longgang Third People's Hospital, Shenzhen, China, Haplox biotechnology Co., Ltd., Shenzhen, Guangdong, China, HaploX Biottechnology Co., Ltd., Shenzhen, Guangdong, China, HaploX Biotechnology, Shenzhen, China, HaploX Biotechnology Co., Ltd, Shenzhen, Guangdong, China, Tianjin Union Medical Center, Tianjin, Tianjin, China, Shenzhen, Guangdong, China, HaploX Biotechnology, Shenzhen, China,
Abstract
The impact of DNA damage repair gene mutations on therapeutic response among Chinese patients diagnosed with advanced biliary tract cancer.Org: Gastric Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, Laboratory of Gastric Cancer, State Key Laboratory of Biotherapy,
Abstract
A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Analysis of survival outcomes in patients with non–small-cell lung cancer with mutations in STK11/LKB1 receiving chemoimmunotherapy.Org: Avera McKennan Hospital & University Health Center, Avera Cancer Institute, Sioux Falls, SD, Avera Cancer Care Institute at Sioux Falls,
Abstract
Clinical and genomic characteristics between DDR germline and somatic mutations in pan-cancer.Org: Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Lab of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing, China,
Abstract
Establishing clinical performance characteristics for Duoseq, a new assay for DNA and RNA sequencing.Org: Data Driven Bioscience, Indiana University – Purdue University Indianapolis, Wake Forest School of Medicine, Winston-Salem, NC, Wake Forest University Department of General Internal Medicine, Indiana University Hospital,
Abstract
Spectrum of germline pathogenic variants among patients with cancer in Mexico.Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico, National Institute of Medical Sciences and Nutrition Salvador Zubirán, City of Hope National Medical Center, Latin American School of Oncology,
Abstract
The polymorphic markers of the XRCC1, ERCC5, TP53, CDKN1A1 genes and the survival of triple negative breast cancer patients after platinum-based chemotherapy.Org: Russian Medical Academy of Continuous Professional Education, Emanuel Institute of Biochemical Physics, Federal Research & Clinical Center of Physical-Chemical Medicine FMBA of Russia, Russian Cancer Research Center N.N. Blokhin, B.I. Kulakov Research National Center of Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation,
Abstract
Blood-based molecular profiling of Chinese patients with advanced renal cell carcinoma.Org: Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, Ningbo Urology & Nephrology Hospital, AcornMed Biotechnology Co., Ltd., Beijing, China,
Abstract
Intratumoral heterogeneity as a predictive biomarker in immunotherapy for advanced esophageal cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Shanghai East Hospital, Tongji University, Shanghai, China, Tongji Universtity School of Medicine,
Abstract
Clinicogenomic analysis of rare histologic variants of pancreatic carcinoma: Undifferentiated carcinomas with and without osteoclast-like giant cells.Org: University of Michigan, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Division of Hepatopancreatobiliary Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, University of Michigan Health System Comprehensive Cancer Center,
Abstract
Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathologic study.Org: University of Kansas Medical Center, Department of Biostatistics & Data Science, Kansas City, MO, KSQ Therapeutics, Cambridge, MA,
Abstract
Class II and class III BRAF mutations in patients with advanced non-small cell lung cancer (NSCLC): Clinical characteristics, mutation patterns, and survival outcomes.Org: Network Genomic Medicine, University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne,
Abstract
FISH abnormalities in Agent Orange–associated multiple myeloma.Org: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland VA Medical Center,
Abstract
Real-world (RW) treatment (tx) patterns of patients (pts) with higher-risk myelodysplastic syndrome (MDS) in a US RWE database (COTA).Org: Novartis Pharma AG, Basel, Switzerland, Novartis Oncology,
Abstract
Utility of multi-gene panel-based germline analysis following genomic profiling and cascade testing in advanced solid tumors: An initial report of the BRANCH study.Org: National Cancer Center Hospital East, Kashiwa, Japan, National Cancer Center Hospital Japan East, Kashiwa, Japan, National Hospital Organization Shikoku Cancer Center, Department of Gastroenterology, Saitama Cancer Center, Saitama-Shi, Japan, Kanagawa Cancer Center,
Abstract
Comprehensive multigene profiling impact on clinical decisions in patients with advanced cancers: A multicenter, retrospective analysis.Org: Federal State Budgetary Institution N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), OncoAtlas LLC, Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology" of the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO),
Abstract
Prognostic value of TP53 mutation status in metastatic triple-negative and hormone receptor-positive breast cancer using cell-free DNA genomic profiling.Org: Mass General Brigham-Salem Hospital, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Massachusetts General Hospital, Massachusetts General Hospital Cancer Center, Harvard Medical School (HMS), Boston, MA, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY,
Abstract
The mutational landscape of circulating cell free DNA in patients with gastric cancer.Org: The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Department of Oncology,Daqing Oilfield Hospotal, Harbin, China, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China, HaploX Biotechnology, Shenzhen, China, China-Japan Union Hospital of Jilin University, Jilin, China,
Abstract
Venetoclax with decitabine or azacitidine in previously untreated TP53mut acute myeloid leukemia.Org: VCU Massey Cancer Center, VCU School of Medicine, VCU Department of Internal Medicine, Virginia Commonwealth University School of Medicine, VCU Department of Biostatistics,
Abstract
Prognostic impact of TP53 mutations in metastatic non-squamous non-small-cell lung cancer.Org: Institut de Cancérologie de l'Ouest, Angers, France, Nantes University Hospital, Nantes Université, CHU Nantes-Department of Hepato-Gastroenterology, Inserm U1308- CAPTuR- Control of cell Activation in Tumor Progression and Therapeutic Resistance,
Abstract
Association of TP53 mutations with the expression of PD-L1 expression and TMB, and R175H could be the predictor of neoantigen.Org: Guangzhou Huayin Health Medical Group Co.,Ltd., Guangzhou Huayin Health Medical Group Co., Ltd,
Abstract
The impact of secondary-type mutations in newly diagnosed acute myeloid leukemia treated with venetoclax and decitabine or azacitidine.Org: VCU School of Medicine, VCU Massey Cancer Center, VCU Department of Internal Medicine, Virginia Commonwealth University School of Medicine, VCU Department of Biostatistics,
Abstract
Serial ctDNA monitoring to predict response in mCRC patients treated with anlotinib in combination with oxaliplatin and capecitabine (CAPEOX) as the first-line therapy.Org: Cancer Center Zhejiang University, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co., Ltd,
Abstract
Performance of the OncoUrine test on the predictive capacity of non-muscle-invasive bladder cancer patients who are candidates for repeated transurethral resection.Org: Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, Jichenjunchuang Medical Laboratory(Hangzhou), Co. Ltd., Hangzhou, China, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China,
Abstract
Clinical outcomes of core binding factor acute myeloid leukemia in the modern era.Org: Virginia Commonwealth University School of Medicine, VCU Massey Cancer Center, VCU School of Medicine, VCU Department of Internal Medicine, VCU Department of Biostatistics,
Abstract
The landscape of ATM alteration in Chinese solid tumor patients.Org: Ya’an People’s Hospital, Yinfeng Gene Technology Co Ltd, Huaxi Kindstar Medical Diagnostics (Sichuan) Co Ltd, Clinical Oncology Research Alliance,
Abstract
Comprehensive genetic characteristics of multiple primary lung cancer in patients in China.Org: Beijing Haidian Hospital, AcornMed Biotechnology Co., Ltd., Beijing, China,
Abstract
The combination of APR-246 and carboplatin in olaparib-resistant high grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC) cell lines.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria (INCLIVA), Translational Oncology and Pathology Group, La Paz University Hospital-IdiPAZ,
Abstract
Combinatorial immune biomarkers of efficacy on buparlisib and paclitaxel in patients with SCCHN: BERIL-1 sub-analysis.Org: Adlai Nortye USA Inc., Adlai Nortye Biopharma, Head and Neck Cancer Medical Oncology 3 Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Department of Oncology and Hemato-Oncology, University of Milan, and Division of Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy,
Abstract
FLAG-IDA or venetoclax in previously treated TP53mut acute myeloid leukemia.Org: VCU Department of Internal Medicine, VCU Massey Cancer Center, VCU School of Medicine, Virginia Commonwealth University School of Medicine, VCU Department of Biostatistics,
Abstract
Anti–PD-1 combination regimen as first-line therapy in advanced biliary tract cancer and biomarker exploration: A retrospective study.Org: The Comprehensive Cancer Centre of Drum Tower Hospital, Clinical Cancer Institute of Nanjing University, Department of Radiology of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Department of Pathology of Nanjing Drum Tower Hospital,
Abstract
The genetics of transformation from myelodysplastic syndrome to secondary acute myeloid leukemia.Org: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Shandong First Medical Universityand Shandong Academy of Medical Sciences, Sino-US Diagnostics Lab,
Abstract
The impact of TP53 mutations and use of the TP53-mutation-reactivating agent APR-246 on metastatic castrate-sensitive prostate cancer.Org: Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University Bloomberg School of Public Health, University of Maryland Capital Region, Johns Hopkins University School of Medicine, Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine,
Abstract
Comprehensive analysis of the mutational status of early colon cancer: Real world data from the AIO ColoPredict registry study.Org: Institut für Pathologie, Georgius Agricola Stiftung Ruhr, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Oncology and Palliative Care Units, Ruhr-University Bochum,
Abstract
An Asian multi-regional registry study of rare cancers: The MASTER KEY ASIA and MASTER KEY Japan projects.Org: Department of International Clinical Development, National Cancer Center Hospital, Tokyo, Japan, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, Tohoku University Hospital, Sendai-Shi Aoba-Ku, MIYAGI-KEN, Japan, Department of Oncology and Social Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, Hokkaido University Hospital, Sapporo-Shi, Japan,
Abstract
Liquid and tissue profiling of somatic mutational landscape of non-small cell lung cancer from an Indian cohort.Org: Sir H N Reliance Foundation Hospital and Research Centre, Mumbai, NY, India, Adana Acıbadem Hospital, Adana, Turkey, St Bartholomew's Hospital, London, United Kingdom, Fortis Cancer Institute, New Delhi, India, Imperial College London, London, United Kingdom,
Abstract
Clinical implications of universal germline testing in breast cancer patients in an Arab population: The Jordanian Exploratory Cancer Genetics (Jo-ECAG) study.Org: King Hussein Cancer Center, Amman, Jordan, Invitae, San Francisco, CA, King Hussien Cancer Center,
Abstract
Comprehensive plasma genotyping reveals mutational signatures that confer resistance to tyrosine kinase inhibitors (TKI) in patients with advanced lung cancer.Org: OneCell Dx, Tata Memorial Hospital (HBNI), OneCell Diagnostics, School of Consciousness, MIT WPU, Indx Technology,
Abstract
High frequency of germline mutations in DDR associated genes SLX4, MSH6, CDK4, TSC2, and BRCA2 might contribute to the occurrence of MPLC.Org: The First People's Hospital of Foshan, Foshan First People's Hospital, China National Biotec Group, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing Simcere Medical Laboratory Science Co., Ltd., The State Key Laboratory of Translational Medicine and Innovative Drug Development at Jiangsu Simcere Diagnostics Co. Ltd,
Abstract
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: The IMMINENT study.Org: University of Verona, Oncology Section, Azienda Ospedaliera Universitaria Integrata di Verona, Ospedale San Bortolo Azienda ULSS8 Berica - Distretto Est, Santa Chiara Hospital, Trento, Italy, Policlinico Universitario Gaspare Rodolico,
Abstract
The genomic landscape and prognostic significance of 11.q.13 amplification in breast, head & neck, and lung cancer.Org: Caris Life Sciences, Irving, TX, Hoag Memor Hosp, University of Cincinnati Medical Center, Brown University - Lifespan Cancer Institute, Hoag Family Cancer Institute and University of Southern California,
Drug
AN0025